{
    "root": "8e571636-526b-4d31-a8ac-c19014a59f9c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Bexagliflozin"
    },
    "value": "20250311",
    "ingredients": [
        {
            "name": "BEXAGLIFLOZIN",
            "code": "EY00JF42FV"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "GLYCERYL DIBEHENATE",
            "code": "R8WTH25YS2"
        },
        {
            "name": "INDIGOTINDISULFONATE SODIUM",
            "code": "D3741U8K7L"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POLOXAMER 188",
            "code": "LQA7B6G8JG"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        }
    ],
    "indications": "bexagliflozin indicated adjunct diet exercise improve glycemic control adults type 2 diabetes mellitus . limitations bexagliflozin recommended improve glycemic control patients type 1 diabetes mellitus . [ ( 5.1 ) ] .",
    "contraindications": "\u2022 recommended dose : 20 mg daily , taken morning , without food . crush chew tablet . ( 2.2 ) \u2022 assess renal function initiating bexagliflozin tablets clinically indicated . correct volume depletion initiating ( 2.1 ) \u2022 recommended egfr less 30 ml/min/1.73 2 . ( 2.1 ) \u2022 withhold bexagliflozin tablets least 3 days , possible , prior major surgery procedures associated prolonged fasting ( 2.3 ) .",
    "warningsAndPrecautions": "bexagliflozin 20 mg tablets blue , caplet-shaped , biconvex , bevel-edged , film-coated debossed \u201c 2 \u201d inverted \u201c 2 \u201d one side . \u2022 bottles 30 tablets \u2013 ndc 82381-2000-8 \u2022 bottles 90 tablets \u2013 ndc 82381-2000-9 storage handling store 20 \u00b0c 25 \u00b0c ( 68 \u00b0f 77 \u00b0f ) ; excursions permitted 15 \u00b0c 30 \u00b0c ( 59 \u00b0f 86 \u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "bexagliflozin tablets contraindicated patients : hypersensitivity bexagliflozin excipient bexagliflozin tablets . anaphylaxis angioedema reported sodium-glucose co-transporter 2 ( sglt2 ) inhibitors .",
    "indications_original": "Bexagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.\n                  \n                     Limitations of Use\n                      Bexagliflozin\u00a0is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus.\u00a0[see\u00a0\n                     Warnings and Precautions (5.1)].",
    "contraindications_original": "\u2022 Recommended dose: 20 mg once daily, taken in the morning, with or without food. Do not crush or chew the tablet. ( 2.2 ) \u2022 Assess renal function before initiating bexagliflozin tablets\u00a0and as clinically indicated. Correct volume depletion before initiating ( 2.1 ) \u2022 Not recommended if eGFR less than 30 mL/min/1.73 m 2 . ( 2.1 ) \u2022 Withhold bexagliflozin tablets\u00a0for at least 3 days, if possible, prior to major surgery or procedures associated with prolonged fasting ( 2.3 ).",
    "warningsAndPrecautions_original": "Bexagliflozin\u00a020 mg tablets are blue, caplet-shaped, biconvex, bevel-edged, film-coated debossed with \u201c2\u201d and inverted \u201c2\u201d on one side. \u00a0\u00a0\u00a0\u00a0\u2022 Bottles of 30 tablets \u2013 NDC 82381-2000-8 \u00a0\u00a0\u00a0\u00a0\u2022 Bottles of 90 tablets \u2013 NDC 82381-2000-9\n                  \n                     Storage and Handling\n                      Store from 20 \u00b0C to 25 \u00b0C (68 \u00b0F to 77 \u00b0F); excursions permitted between 15 \u00b0C to 30 \u00b0C (59 \u00b0F to 86 \u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Bexagliflozin tablets are contraindicated in patients:\n                  \n                     With hypersensitivity to bexagliflozin or any excipient in bexagliflozin tablets. Anaphylaxis and angioedema have been reported with sodium-glucose co-transporter 2 (SGLT2) inhibitors."
}